| Year |
Citation |
Score |
| 2023 |
Salam R, Saliou A, Bielle F, Bertrand M, Antoniewski C, Carpentier C, Alentorn A, Capelle L, Sanson M, Huillard E, Bellenger L, Guégan J, Le Roux I. Cellular senescence in malignant cells promotes tumor progression in mouse and patient Glioblastoma. Nature Communications. 14: 441. PMID 36707509 DOI: 10.1038/s41467-023-36124-9 |
0.394 |
|
| 2023 |
Laurenge A, Huillard E, Bielle F, Idbaih A. Cell of Origin of Brain and Spinal Cord Tumors. Advances in Experimental Medicine and Biology. 1394: 85-101. PMID 36587383 DOI: 10.1007/978-3-031-14732-6_6 |
0.343 |
|
| 2021 |
Magne N, Rousseau V, Duarte K, Poëa-Guyon S, Gleize V, Mutel A, Schmitt C, Castel H, Idbaih A, Huillard E, Sanson M, Barnier JV. PAK3 is a key signature gene of the glioma proneural subtype and affects its proliferation, differentiation and growth. Cellular Oncology (Dordrecht). PMID 34550532 DOI: 10.1007/s13402-021-00635-8 |
0.341 |
|
| 2019 |
Blomfield IM, Rocamonde B, Masdeu MDM, Mulugeta E, Vaga S, van den Berg DL, Huillard E, Guillemot F, Urbán N. Id4 promotes the elimination of the pro-activation factor Ascl1 to maintain quiescence of adult hippocampal stem cells. Elife. 8. PMID 31552825 DOI: 10.7554/eLife.48561 |
0.301 |
|
| 2019 |
Seano G, Griveau A, Shelton S, Krishnan S, Wang N, Kloepper J, Huillard E, Batchelor T, Stemmer-Rachamimov A, Aghi M, Jain R, Rowitch D. OS12.4 In vivo dynamics and targeting of vessel co-option in glioma Neuro-Oncology. 21: iii23-iii23. DOI: 10.1093/Neuonc/Noz126.076 |
0.621 |
|
| 2018 |
Griveau A, Seano G, Shelton SJ, Kupp R, Jahangiri A, Obernier K, Krishnan S, Lindberg OR, Yuen TJ, Tien AC, Sabo JK, Wang N, Chen I, Kloepper J, Larrouquere L, ... ... Huillard E, et al. A Glial Signature and Wnt7 Signaling Regulate Glioma-Vascular Interactions and Tumor Microenvironment. Cancer Cell. PMID 29681511 DOI: 10.1016/J.Ccell.2018.03.020 |
0.633 |
|
| 2016 |
Lindberg OR, McKinney A, Engler JR, Koshkakaryan G, Gong H, Robinson AE, Ewald AJ, Huillard E, James CD, Molinaro AM, Shieh JT, Phillips JJ. GBM heterogeneity as a function of variable epidermal growth factor receptor variant III activity. Oncotarget. PMID 27738329 DOI: 10.18632/Oncotarget.12600 |
0.471 |
|
| 2015 |
Labreche K, Simeonova I, Kamoun A, Gleize V, Chubb D, Letouzé E, Riazalhosseini Y, Dobbins SE, Elarouci N, Ducray F, de Reyniès A, Zelenika D, Wardell CP, Frampton M, Saulnier O, ... ... Huillard E, et al. TCF12 is mutated in anaplastic oligodendroglioma. Nature Communications. 6: 7207. PMID 26068201 DOI: 10.1038/Ncomms8207 |
0.324 |
|
| 2015 |
Griveau A, Shelton S, Tien A, Seano G, Yuen T, Sabo J, Lau J, Jahangiri A, Huillard E, Phillips J, Persson A, Oldham M, Weiss W, Aghi M, Stiles C, et al. ANGI-04Olig2 REGULATES Wnt7b EXPRESSION AND VASCULATURE CHARACTERISTICS IN GLIOMA Neuro-Oncology. 17: v41.4-v41. DOI: 10.1093/Neuonc/Nov207.04 |
0.627 |
|
| 2014 |
Simeonova I, Huillard E. In vivo models of brain tumors: roles of genetically engineered mouse models in understanding tumor biology and use in preclinical studies. Cellular and Molecular Life Sciences : Cmls. 71: 4007-26. PMID 25008045 DOI: 10.1007/S00018-014-1675-3 |
0.413 |
|
| 2012 |
Huillard E, Hashizume R, Phillips JJ, Griveau A, Ihrie RA, Aoki Y, Nicolaides T, Perry A, Waldman T, McMahon M, Weiss WA, Petritsch C, James CD, Rowitch DH. Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy. Proceedings of the National Academy of Sciences of the United States of America. 109: 8710-5. PMID 22586120 DOI: 10.1073/Pnas.1117255109 |
0.539 |
|
| 2012 |
Phillips JJ, Huillard E, Robinson AE, Ward A, Lum DH, Polley MY, Rosen SD, Rowitch DH, Werb Z. Heparan sulfate sulfatase SULF2 regulates PDGFRα signaling and growth in human and mouse malignant glioma. The Journal of Clinical Investigation. 122: 911-22. PMID 22293178 DOI: 10.1172/Jci58215 |
0.591 |
|
| 2012 |
Papagiannakopoulos T, Friedmann-Morvinski D, Neveu P, Dugas JC, Gill RM, Huillard E, Liu C, Zong H, Rowitch DH, Barres BA, Verma IM, Kosik KS. Pro-neural miR-128 is a glioma tumor suppressor that targets mitogenic kinases. Oncogene. 31: 1884-95. PMID 21874051 DOI: 10.1038/Onc.2011.380 |
0.533 |
|
| 2011 |
Mehta S, Huillard E, Kesari S, Maire CL, Golebiowski D, Harrington EP, Alberta JA, Kane MF, Theisen M, Ligon KL, Rowitch DH, Stiles CD. The central nervous system-restricted transcription factor Olig2 opposes p53 responses to genotoxic damage in neural progenitors and malignant glioma. Cancer Cell. 19: 359-71. PMID 21397859 DOI: 10.1016/J.Ccr.2011.01.035 |
0.601 |
|
| 2010 |
Huillard E, Ziercher L, Blond O, Wong M, Deloulme JC, Souchelnytskyi S, Baudier J, Cochet C, Buchou T. Disruption of CK2beta in embryonic neural stem cells compromises proliferation and oligodendrogenesis in the mouse telencephalon. Molecular and Cellular Biology. 30: 2737-49. PMID 20368359 DOI: 10.1128/Mcb.01566-09 |
0.43 |
|
| 2010 |
Ihrie RA, Huillard E, Petritsch C, James D, McMahon M, Gutmann DH, Rowitch DH, Alvarez-Buylla A. Abstract 4186: Development of a novel, genetically faithful model of pediatric glioblastoma Cancer Research. 70: 4186-4186. DOI: 10.1158/1538-7445.Am10-4186 |
0.48 |
|
| 2008 |
Schüller U, Heine VM, Mao J, Kho AT, Dillon AK, Han YG, Huillard E, Sun T, Ligon AH, Qian Y, Ma Q, Alvarez-Buylla A, McMahon AP, Rowitch DH, Ligon KL. Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma. Cancer Cell. 14: 123-34. PMID 18691547 DOI: 10.1016/J.Ccr.2008.07.005 |
0.633 |
|
| 2007 |
Ligon KL, Huillard E, Mehta S, Kesari S, Liu H, Alberta JA, Bachoo RM, Kane M, Louis DN, Depinho RA, Anderson DJ, Stiles CD, Rowitch DH. Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma. Neuron. 53: 503-17. PMID 17296553 DOI: 10.1016/J.Neuron.2007.01.009 |
0.629 |
|
| Show low-probability matches. |